[1] Marcellin P,Gane E,Buti M,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet,2012,11:1-8.
[2] Duval F,Moreno-Cuevas JE,González-Garza MT,et al. Liver fibrosis and mechanisms of the protective action of medicinal plants targeting inflammation and the immune response. Int J Inflam,2015,2015:943497.
[3] Duval F,Moreno-Cuevas JE,González-Garza MT,et al. Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis. Chin Med,2014,9（1）:27.
[4] Xu R,Zhang Z,Wang FS. Liver fibrosis:mechanisms of immune-mediated liver injury. Cell Mol Immunol. 2012,9（4）:296-301.
[5] Trautwein C,Friedman SL,Schuppan D,et al. Hepatic fibrosis: Concept to treatment. J Hepatol,2015,62（1 Suppl）:S15-24.
[6] Boursier J,Louvet A. Liver fibrogenesis and genetic factors. Clin Res Hepatol Gastroenterol,2011,35:3-9.
[7] Ramezani A,Banifazl M,Mamishi S. The influence of human leukocyte antigen and IL-10 gene polymorphisms on hepatitis B virus outcome. Hepat Mon,2012,12:320-325.
[8] Andres DR,Jose TA,Jordan JF. Nonivasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol,2012,11:426-439.
[9] Germani G,Hytiroglou P,Fotiadu A,et al. Assessment of fibrosis and cirrhosis in liver biopsies:an update. Semin Liver Dis,2011,31:82-90.
[10] Zeng MD,Lu LG,Mao YM,et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology,2005,42:1437-1445.
[11] Jin W,Lin Z. Diagnostic accuracy of the asparrate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis:a leading meta-analysis. BMC Gastroenterol,2012,12:14.
[12] Castara L,Sebastiani G,Le Bail B,et a1．Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C．J Hepatol,2010,52:191-198．
[13] Zandieh A,Payabvash S,Pasalar P,et al. Gadolinium chloride, a Kupffer cell inhibitor,attenuates hepatic injury in a rat model of chronic cholestasis. Hum Exp Toxicol,2011,30:1804-1810. |
